Acute Heart Failure - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Acute Heart Failure - Pipeline Review, H2 2016

Acute Heart Failure - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Acute Heart Failure - Pipeline Review, H2 2016
Published Jul 13, 2016
70 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Acute Heart Failure - Pipeline Review, H2 2016, provides an overview of the Acute Heart Failure pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Heart Failure and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure
- The report reviews pipeline therapeutics for Acute Heart Failure by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Heart Failure therapeutics and enlists all their major and minor projects
- The report assesses Acute Heart Failure therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Heart Failure

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Heart Failure
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and

  
Source:
Document ID
GMDHC8234IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Acute Heart Failure Overview71
Therapeutics Development81
  Pipeline Products for Acute Heart Failure Overview81
Acute Heart Failure Therapeutics under Development by Companies91
Acute Heart Failure Pipeline Products Glance103
  Late Stage Products101
  Clinical Stage Products111
  Early Stage Products121
Acute Heart Failure Products under Development by Companies131
Acute Heart Failure Companies Involved in Therapeutics Development148
  Amgen Inc.141
  Capricor Therapeutics, Inc.151
  Eli Lilly and Company161
  Lee's Pharmaceutical Holdings Limited171
  Novartis AG181
  Ono Pharmaceutical Co., Ltd.191
  PhaseBio Pharmaceuticals, Inc.201
  Trevena, Inc.211
Acute Heart Failure Therapeutics Assessment229
  Assessment by Monotherapy Products221
  Assessment by Target232
  Assessment by Mechanism of Action252
  Assessment by Route of Administration272
  Assessment by Molecule Type292
Drug Profiles3124
  cenderitide Drug Profile313
  istaroxime Drug Profile342
  omecamtiv mecarbil MR Drug Profile367
  ONO-4232 Drug Profile431
  PB-1046 Drug Profile442
  ruboxistaurin Drug Profile462
  serelaxin Drug Profile484
  TRV-120023 Drug Profile521
  ularitide Drug Profile532
Acute Heart Failure Dormant Projects551
Acute Heart Failure Discontinued Products561
Acute Heart Failure Product Development Milestones5712
  Featured News &Press Releases571
    Dec 11, 2015: Cardiorentis' Ularitide Receives FDA Fast Track Designation for the Treatment of Acute Decompensated Heart Failure571
    May 22, 2015: Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure571
    Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide581
    Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation581
    May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure591
    May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure591
    Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome601
    Mar 25, 2014: FDA Staff Says Novartis Serelaxin Shouldn t Be Approved601
    Jan 24, 2014: Novartis Europharm's Reasanz Receives CHMP Negative Opinion611
    Jan 24, 2014: Novartis to request re-examination of serelaxin in acute heart failure for conditional marketing authorization in EU621
    Dec 02, 2013: Paladin Announces Filing of New Drug Submission for RLX030 (Serelaxin)631
    Sep 03, 2013: Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil632
    Sep 02, 2013: Novartis' serelaxin improved symptoms and mortality across multiple subgroups of patients with acute heart failure651
    Jun 21, 2013: Novartis's Serelaxin Receives FDA Breakthrough Therapy Designation For Acute Heart Failure661
    Mar 18, 2013: Cytokinetics Announces Update To Heart Failure Program672
Appendix692
  Methodology691
  Coverage691
  Secondary Research691
  Primary Research691
  Expert Panel Validation691
  Contact Us691
  Disclaimer701

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Acute Heart Failure - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Acute-Heart-Failure-Pipeline-Review-H2-2016-2088-16167>
  
APA:
Global Markets Direct - Market Research. (2016). Acute Heart Failure - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Acute-Heart-Failure-Pipeline-Review-H2-2016-2088-16167>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.